RxDoctor Payments DataLook up a doctor →

Samir Bangalore, MD

Epilepsy · Nashville, TNNPI 1043423874

Payments from drug & device makers

$134,371in general payments, 2019–2025

Across 606 payments — averaging $221.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$59K
  • UCB, Inc.$59K
  • Eisai Inc.$6K
  • Acadia Pharmaceuticals Inc$2K
  • Neurelis, Inc.$1K
  • Livanova USA, Inc.$988
  • plus $6K from 46 others

What the payments were for

  • Consulting fees$7,3305%
  • Speaking & faculty fees$102,22576%
  • Travel & lodging$8,6176%
  • Food & beverage$16,14012%
  • Education$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few epilepsy providers in Tennesseeto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$90,033
Medicare patients
275
Services billed
814

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$90,891
BriviactBrivaracetam28$43,026
AptiomEslicarbazepine Acetate11$14,399
Lacosamide38$6,850
Lamotrigine ErLamotrigine18$4,338
Levetiracetam65$2,861
Carbamazepine ErCarbamazepine13$1,899
Levetiracetam ErLevetiracetam16$1,330
Lamotrigine69$1,275
Clobazam11$1,161
Divalproex Sodium ErDivalproex Sodium22$1,038
Topiramate24$654
Zonisamide29$562
Sodium Chloride0.9 % Sodium Chloride11$185
Clonazepam14$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$58,666$43,02628 claims
Sunovion Pharmaceuticals Inc.Aptiom$506$14,39911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few epilepsy providers in Tennesseeon file to place this against a meaningful peer group, so we don't.

Other epilepsy in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →